Mesoblast

Mesoblast applies a proprietary mesenchymal lineage cell platform to a portfolio of allogeneic, off-the-shelf cell therapy candidates for severe, life-threatening inflammatory and degenerative conditions. Its candidates include remestemcel-L for acute GVHD and ARDS, REVASCOR for advanced chronic heart failure, and MPC-06-ID for chronic low back pain from degenerative disc disease. Mesenchymal lineage cells collected from bone marrow donors are expanded into a uniform, reproducible population suitable for industrial-scale manufacturing.

Mesoblast administers its cell therapies without donor-recipient matching or immune suppression. Ryoncil (remestemcel-L) addresses steroid-refractory acute graft-versus-host disease in children aged two months and older, and stands as the first FDA-approved mesenchymal stromal cell therapy. Development also continues for adults with steroid-refractory acute GVHD and for biologic-resistant inflammatory bowel disease using Ryoncil, while rexlemestrocel-L targets heart failure as well as chronic low back pain.